Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-01

Clinical Trial Update: An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

An extension study (Phase 3) in participants with moderate to severe rheumatoid arthritis has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Eli Lilly and Company | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-02-01